Medical Information

Ribociclib plays an important role in various cancer treatments, but not all patients are suitable. There are significant risks associated with the use of this drug in patients with severe liver and kidney dysfunction and QTc prolongation, and strict screening must be conducted before medication.

1、 Severe liver and kidney dysfunction patients

1. Severe liver damage

Child Pugh C grade (severe liver damage) patients are contraindicated. The drug clearance ability of this group of people is severely reduced, leading to an abnormal increase in blood drug concentration and a significant increase in toxicity risk. Liver function grading assessment should be completed before medication.

2. Severe kidney damage

Patients with creatinine clearance rate<30mL/min are prohibited from using it. Severe decline in renal function can affect the excretion of Ribociclib and its metabolites, increasing the likelihood of drug accumulation.

3. Handling of mild to moderate abnormalities

Mild to moderate liver or kidney damage is not an absolute contraindication, but should be used with caution. If necessary, dosage should be reduced, and liver function, kidney function, and blood electrolyte monitoring should be strengthened.

2、 Individuals at risk of QTc prolongation and arrhythmia

1. Patients with significantly prolonged baseline QTc

QTc interval>480 milliseconds is prohibited. Ribociclib can further prolong ventricular repolarization time, increase the risk of apical torsion ventricular tachycardia and sudden death.

2. Key populations that require special attention

This includes patients with congenital long QT syndrome, uncontrolled or severe heart disease (such as recent myocardial infarction, heart failure), and electrolyte imbalances (especially hypokalemia and hypomagnesemia).

3. Combination use of other QTc prolonging drugs

When using antiarrhythmic drugs, certain antibiotics, antipsychotics, and other drugs that can prolong QTc, it is also a high-risk situation and should be avoided in combination.

3、 Key points of pre medication screening and continuous monitoring

1. Baseline check

Blood electrolytes (potassium, magnesium, calcium) must be tested and any abnormalities corrected before treatment. Simultaneously complete the electrocardiogram to confirm that QTc is within a safe range. Assess liver and kidney function, clarify Child Pugh grading and creatinine clearance rate.

2. Monitoring during treatment

At the beginning of the first cycle, electrocardiograms and electrolytes should be rechecked every 2 weeks, and subsequent cycles should be rechecked regularly according to clinical needs. If QTc is prolonged to>480 milliseconds, medication should be suspended, and the influencing factors should be corrected before reassessing whether to reduce and restore. Liver and kidney function should also be regularly rechecked, and any abnormalities should be promptly adjusted according to the plan.